Clinical Trials Browser

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT04734730 2026-01-28

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Phase 2 Recruiting

70 enrolled

Genitourinary

Prostatic Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

24 enrolled

Breast

Breast Neoplasms

NCT02286687 2026-01-02

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

Phase 2 Active not recruiting

150 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT05873192 2025-12-23

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

Phase 2 Recruiting

30 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

TAPUR

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

I-SPY

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

Talazoparib

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer